Oncology

Treatment with the myxoma virus reduced tumor burden and led to a modest decrease in disease progression in mice.

Patients who received phone counseling were more likely to quit smoking than patients who received a list of low cost services.

Top news of the week in oncology and cancer drug development.

PI3K inhibitors loaded into nanoparticles provided targeted treatment for head and neck cancers.

Recombinant shell nanoparticles could deliver drugs straight to cancer cells.

Sarcopenia identified as an independent risk factor.

African American patients are more likely to be diagnosed with advanced cancer and have higher mortality.

Premenopausal African American women with a p35 mutation may be at a higher risk of developing breast cancer.

Top news of the day from across the health care landscape.

Drug may offer an effective alternative to chemotherapy for patients with leukemia.

Combination treatment helped increase invasive disease-free survival in patients with an aggressive type of early breast cancer.

Analysis confirms the safety and efficacy of palliative radiation therapy for painful bone metastases.

Carcinoid syndrome affects some patients with carcinoid tumors.

Investigational drug treats patients with relapsed or refractory AML with an isocitrate dehydrogenase 2 mutation.

Xermelo plus somatostatin analog therapy approved to treat carcinoid diarrhea syndrome.

Top news of the day from across the health care landscape.

Combination therapy shows promise treating pancreatic cancer.

Nab-paclitaxel prevents proliferation, and increases immune system response to cancer cells.

G-CSF promotes regeneration of sperm cells in cancer patients.

A majority of glioblastomas change their genomic profile during therapy, new research finds.

Targeting the interactions between neurons and cancer cells may be a powerful strategy in future cancer treatments.

Top news of the day from across the health care landscape.

Researchers create a map of breast cancer cell shapes and genes that is linked to outcomes.

Mapping cancer cells to genes helps to formulate a treatment plan.

One-fourth of standard dose with low-fat meal as effective as standard dose.

Marc O'Connor, COO and chief strategy officer at Curant Health, discusses how the shift to Medicare Part D could impact patients undergoing treatment for cancer.

Lynparza (olaparib) shows efficacy in a phase 3 clinical trial of BRCA-mutated HER2-negative metastatic breast cancer.

The phase 3 OLYMPIAD clinical trial met its primary endpoint of progression-free survival in breast cancer.

New technology can predict which patients will achieve remission and which will relapse.

Young children had more than twice the risk for overdose compared to children whose mothers were prescribed nonsteroidal anti-inflammatory drugs (NSAIDs) rather than opioids.